CoChat
Sign Up
Cited by 293GDF15 and Related BiomarkersMitochondrial Function and PathologyMetabolism and Genetic Disorders

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders

Open access
Yatsuga, Shuichi, Fujita, Yasunori, Ishii, Akiko, Fukumoto, Yoshihiro, Arahata, Hajime, Kakuma, Tatsuyuki, Kojima, Toshio, Ito, Masafumi, Tanaka, Masashi, Saiki, Reo, Koga, Yasutoshi·2015·Annals of Neurology
DOI 10.1002/ana.24506PMC PMC5057301
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: The diagnosis of mitochondrial disorders (MDs) is occasionally difficult because patients often present with solitary, or a combination of, symptoms caused by each organ insufficiency, which may be the result of respiratory chain enzyme deficiency. Growth differentiation factor 15 (GDF-15) has been reported to be elevated in serum of patients with MDs. In this study, we investigated whether GDF-15 is a more useful biomarker for MDs than several conventional biomarkers. METHODS: We measured the serum levels of GDF-15 and fibroblast growth factor 21 (FGF-21), as well as other biomarkers, in 48 MD patients and in 146 healthy controls in Japan. GDF-15 and FGF-21 concentrations were measured by enzyme-linked immunosorbant assay and compared with lactate, pyruvate, creatine kinase, and the lactate-to-pyruvate ratio. We calculated sensitivity and specificity and also evaluated the correlation based on two rating scales, including the Newcastle Mitochondrial Disease Rating Scale (NMDAS). RESULTS: Mean GDF-15 concentration was 6-fold higher in MD patients compared to healthy controls (2,711 ± 2,459 pg/ml vs 462.5 ± 141.0 pg/mL; p < 0.001). Using a receiver operating characteristic curve, the area under the curve was significantly higher for GDF-15 than FGF-21 and other conventional biomarkers. Our date suggest that GDF-15 is the most useful biomarker for MDs of the biomarkers examined, and it is associated with MD severity. INTERPRETATION: Our results suggest that measurement of GDF-15 is the most useful first-line test to indicate the patients who have the mitochondrial respiratory chain deficiency.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.24506

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 STARD flow diagram and demography of the controls, MD patients, and disease controls. (A) All 48 MD patients who fulfilled the clinical diagnostic criteria (mitochondrial encephalopathy, lactic acidosis, and stroke‐like episodes [MELAS]; mitochondrial encephalopathy, and lactic acidosis [MELA], for which the main symptom was muscle weakness; Leigh syndrome [LS]; overlapping MELAS/LS; and Kearns‐Sayre syndrome [KSS]) and carried a known genetic abnormality were enrolled in this study from 2005 to 2013. (B) Healthy adult and child volunteers without treatment or ambulatory medical care were also recruited in 146 Japanese. MD = mitochondrial disorder; STARD = standards for reporting of diagnostic accuracy.
Figure 1 STARD flow diagram and demography of the controls, MD patients, and disease controls. (A) All 48 MD patients who fulfilled the clinical diagnostic criteria (mitochondrial encephalopathy, lactic acidosis, and stroke‐like episodes [MELAS]; mitochondrial encephalopathy, and lactic acidosis [MELA], for which the main symptom was muscle weakness; Leigh syndrome [LS]; overlapping MELAS/LS; and Kearns‐Sayre syndrome [KSS]) and carried a known genetic abnormality were enrolled in this study from 2005 to 2013. (B) Healthy adult and child volunteers without treatment or ambulatory medical care were also recruited in 146 Japanese. MD = mitochondrial disorder; STARD = standards for reporting of diagnostic accuracy.CC BY-NC · PubMed Central
Figure 2 All biomarker concentrations for MDs and controls, and demography between MDs and non‐MDs patients. (A) GDF‐15, (B) FGF‐21, (C) lactate:pyruvate ratio, (D) lactate, (E) pyruvate, and (F) CK. MD patients exhibited significantly higher levels of all biomarkers compared to controls. CK = creatine kinase; FGF‐21 = fibroblast growth factor 21; GDF‐15 = growth differentiation factor 15; MD = mitochondrial disorder.
Figure 2 All biomarker concentrations for MDs and controls, and demography between MDs and non‐MDs patients. (A) GDF‐15, (B) FGF‐21, (C) lactate:pyruvate ratio, (D) lactate, (E) pyruvate, and (F) CK. MD patients exhibited significantly higher levels of all biomarkers compared to controls. CK = creatine kinase; FGF‐21 = fibroblast growth factor 21; GDF‐15 = growth differentiation factor 15; MD = mitochondrial disorder.CC BY-NC · PubMed Central
Figure 3 Comparison of biomarkers for MDs, and GDF‐15 and FGF‐21 concentrations for MDs and non‐MDs. GDF‐15 and FGF‐21 concentrations in the patients who suffered from MD subtypes, DMD, MS, optic neuritis, limbic encephalitis, brainstem encephalitis, menigoencephalitis, SLE with CNS, NMO, and HUS encephalitis, and HF, and the control group are shown. Each MD subtype displayed significantly higher levels of GDF‐15 and FGF‐21 than the control group. HF displayed significantly higher levels of only GDF‐15 than the control group. (A) GDF‐15 and (B) FGF‐21. CNS = central nervous system; DMD = Duchenne muscular dystrophy; FGF‐21 = fibroblast growth factor 21; GDF‐15 = growth differentiation factor 15; HUS = hemolytic uremic syndrome; KSS = Kearns‐Sayre syndrome; LS = Leigh syndrome; MD = mitochondrial disorder; MS = multiple sclerosis; MELA = mitochondrial encephalopathy, lactic acidosis (mitochondrial myopathy); MELAS = mitochondrial encephalopathy, lactic acidosis, and stroke‐like episodes; NMO = neuromyelitis optica; SLE = systemic lupus erythematosus.
Figure 3 Comparison of biomarkers for MDs, and GDF‐15 and FGF‐21 concentrations for MDs and non‐MDs. GDF‐15 and FGF‐21 concentrations in the patients who suffered from MD subtypes, DMD, MS, optic neuritis, limbic encephalitis, brainstem encephalitis, menigoencephalitis, SLE with CNS, NMO, and HUS encephalitis, and HF, and the control group are shown. Each MD subtype displayed significantly higher levels of GDF‐15 and FGF‐21 than the control group. HF displayed significantly higher levels of only GDF‐15 than the control group. (A) GDF‐15 and (B) FGF‐21. CNS = central nervous system; DMD = Duchenne muscular dystrophy; FGF‐21 = fibroblast growth factor 21; GDF‐15 = growth differentiation factor 15; HUS = hemolytic uremic syndrome; KSS = Kearns‐Sayre syndrome; LS = Leigh syndrome; MD = mitochondrial disorder; MS = multiple sclerosis; MELA = mitochondrial encephalopathy, lactic acidosis (mitochondrial myopathy); MELAS = mitochondrial encephalopathy, lactic acidosis, and stroke‐like episodes; NMO = neuromyelitis optica; SLE = systemic lupus erythematosus.CC BY-NC · PubMed Central
Figure 4 Correlation coefficients between levels of GDF‐15 and FGF‐21 and the JMDRS and NMDAS. GDF‐15 and FGF‐21 levels were positively correlated with the JMDRS and NMDAS: GDF‐15: r = 0.76 (A: p < 0.001) for the JMDRS and r = 0.67 (B: p < 0.001) for the NMDAS; FGF‐21: r = 0.69 (C: p < 0.001) for the JMDRS and r = 0.59 (D: p < 0.001) for the NMDAS. Spearman correlation coefficients were calculated for the statistical analysis. FGF‐21 = fibroblast growth factor 21; GDF‐15 = growth differentiation factor 15; JMDRS = Japanese Mitochondrial Disease Rating Scale; KSS = Kearns‐Sayre syndrome; LS = Leigh syndrome; MELA = mitochondrial encephalopathy, lactic acidosis (mitochondrial myopathy); NMDAS = Newcastle Mitochondrial Disease Adult Scale.
Figure 4 Correlation coefficients between levels of GDF‐15 and FGF‐21 and the JMDRS and NMDAS. GDF‐15 and FGF‐21 levels were positively correlated with the JMDRS and NMDAS: GDF‐15: r = 0.76 (A: p < 0.001) for the JMDRS and r = 0.67 (B: p < 0.001) for the NMDAS; FGF‐21: r = 0.69 (C: p < 0.001) for the JMDRS and r = 0.59 (D: p < 0.001) for the NMDAS. Spearman correlation coefficients were calculated for the statistical analysis. FGF‐21 = fibroblast growth factor 21; GDF‐15 = growth differentiation factor 15; JMDRS = Japanese Mitochondrial Disease Rating Scale; KSS = Kearns‐Sayre syndrome; LS = Leigh syndrome; MELA = mitochondrial encephalopathy, lactic acidosis (mitochondrial myopathy); NMDAS = Newcastle Mitochondrial Disease Adult Scale.CC BY-NC · PubMed Central
Figure 5 Correlation between GDF‐15 and FGF‐21 for MDs. GDF‐15 and FGF‐21 levels were positively correlated for mitochondrial disorders (MDs): r = 0.64 (p < 0.001). Spearman correlation coefficients were calculated for the statistical analysis. FGF‐21 = fibroblast growth factor 21; GDF‐15 = growth differentiation factor 15.
Figure 5 Correlation between GDF‐15 and FGF‐21 for MDs. GDF‐15 and FGF‐21 levels were positively correlated for mitochondrial disorders (MDs): r = 0.64 (p < 0.001). Spearman correlation coefficients were calculated for the statistical analysis. FGF‐21 = fibroblast growth factor 21; GDF‐15 = growth differentiation factor 15.CC BY-NC · PubMed Central
Figure 6 ROC curves for each biomarker in the MD patients. AUC values were 0.997 (95% confidence interval [CI]: 0.993–1.000) for GDF‐15, 0.919 (95% CI: 0.865–0.973) for the lactate‐to‐pyruvate ratio, 0.889 (95% CI: 0.837–0.962) for FGF‐21, 0.882 (95% CI: 0.814–0.950) for lactate, 0.706 (95% CI: 0.614–0.798) for pyruvate, and 0.609 (95% CI: 0.506–0.711) for creatine kinase (CK). AUC = area under the curve; FGF‐21 = fibroblast growth factor 21; GDF‐15 = growth differentiation factor 15; L/P ratio = lactate‐to‐pyruvate ratio; MD = mitochondrial disorder; ROC = receiver operating characteristic.
Figure 6 ROC curves for each biomarker in the MD patients. AUC values were 0.997 (95% confidence interval [CI]: 0.993–1.000) for GDF‐15, 0.919 (95% CI: 0.865–0.973) for the lactate‐to‐pyruvate ratio, 0.889 (95% CI: 0.837–0.962) for FGF‐21, 0.882 (95% CI: 0.814–0.950) for lactate, 0.706 (95% CI: 0.614–0.798) for pyruvate, and 0.609 (95% CI: 0.506–0.711) for creatine kinase (CK). AUC = area under the curve; FGF‐21 = fibroblast growth factor 21; GDF‐15 = growth differentiation factor 15; L/P ratio = lactate‐to‐pyruvate ratio; MD = mitochondrial disorder; ROC = receiver operating characteristic.CC BY-NC · PubMed Central
Figure 7 GDF‐15 concentrations in the healthy controls reported from literatures. GDF‐15 concentrations were recruited from literatures measured by the same ELISA kit (R&D Systems, Minneapolis, MN), that are a13, b14, c8, d15, e16, f17, g18, h19, and i (our data). Data are shown in mean ± standard deviation (SD). References of a13, d15, and h19 are not described in SD. The number in parenthesis shows sample number. Our GDF‐15 level in the healthy controls was similar to previous literatures.8, 13, 14, 15, 16, 17, 18, 19 GDF‐15 = growth differentiation factor 15.
Figure 7 GDF‐15 concentrations in the healthy controls reported from literatures. GDF‐15 concentrations were recruited from literatures measured by the same ELISA kit (R&D Systems, Minneapolis, MN), that are a13, b14, c8, d15, e16, f17, g18, h19, and i (our data). Data are shown in mean ± standard deviation (SD). References of a13, d15, and h19 are not described in SD. The number in parenthesis shows sample number. Our GDF‐15 level in the healthy controls was similar to previous literatures.8, 13, 14, 15, 16, 17, 18, 19 GDF‐15 = growth differentiation factor 15.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 293

Related

See all

Metadata

Authors
Yatsuga, S., Fujita, Y., Ishii, A., Fukumoto, Y., Arahata, H., Kakuma, T., Kojima, T., Ito, M., Tanaka, M., Saiki, R., & Koga, Y.
Affiliations
  • Kurume University (JP)
  • Tokyo Metropolitan Institute of Gerontology (JP)
  • University of Tsukuba (JP)
  • Omuta hospital (JP)
  • Toyohashi University of Technology (JP)
Corresponding author
Koga, Yasutoshi
ORCID
Venue
Annals of Neurology
Publisher
Wiley
Published
2015-10-14
Volume
78
Issue
5
Pages
814-823
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
DOI
10.1002/ana.24506
PMC
PMC5057301
OpenAlex
W1903699046
Cited by
293
References
25
Citations by year
2026: 26 · 2025: 29 · 2024: 29 · 2023: 24 · 2022: 32 · 2021: 35 · 2020: 41 · 2019: 31 · 2018: 14 · 2017: 18 · 2016: 13
FWCI
12.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Neurology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (publishedVersion)
  • Terrestrial Environment Research Center (University of Tsukuba) (submittedVersion)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology (MEXT) (25461571 (to Y.K.), 25860891 (to S.Y.), 25242062 (to M.T.))
  • The Ministry of Health, Labor and Welfare of Japan. (24-Nanchi-Ippan-005 (to Y.K.) for Research on Intractable Diseases)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › GDF15 and Related Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
growth differentiation factor 15, mitochondrial disease, biomarkers, FGF21, respiratory chain deficiency, serum biomarkers, disease severity, sensitivity and specificity
MeSH terms
Adolescent, Adult, Child, Creatine Kinase, Female, Fibroblast Growth Factors, Humans, Male, Middle Aged, ROC Curve, Biomarkers, MELAS Syndrome, Pyruvic Acid, Lactic Acid, Mitochondrial Diseases, Growth Differentiation Factor 15, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review